Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-alzheimer agents

Current Pharmaceutical Design

Volumn 16, Issue 25, 2010, Pages 2818-2836

  Galdeano, Carles ^a   Viayna, Elisabet ^a   Arroyo, Pau ^b   Bidon Chanal, Axel ^a   Blas, J Ramón ^a   Muñoz Torrero, Diego ^a   Luque, F Javier ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Acetylcholinesterase; Bace 1; Butyrylcholinesterase; Drug target interactions; Structure based drug design

Indexed keywords

8 ( 2,6 DIMETHYLMORPHOLINO)OCTYLCARBAMOYLESEROLINE; ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMINOPYRIDINE DERIVATIVE; AMYLOID BETA PROTEIN; AP 2238; BETA SECRETASE; BETA SECRETASE INHIBITOR; BUTYRYLCHOLINESTERASE 1; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DECAMETHONIUM; DONEPEZIL; GALANTAMINE; GALLAMINE; HUPERZINE A; HUPRINE X; MF 268; NEUROMUSCULAR DEPOLARIZING AGENT; NF 595; NOOTROPIC AGENT; PEPTIDOMIMETIC AGENT; PHYSOSTIGMINE; PHYSOSTIGMINE DERIVATIVE; PROPIDIUM IODIDE; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TACRINE; THIOFLAVINE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHOSTIGMINE;

ALZHEIMER DISEASE; ARTICLE; CATALYSIS; COMPLEX FORMATION; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG BINDING SITE; DRUG INHIBITION; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HYDROLYSIS; IC 50; NEUROTRANSMISSION; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

EID: 77957932175     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793176536     Document Type: Article

References (128)

1. Alzheimer's Association. Alzheimer's disease facts and figures.Alzheimers Dementia 2009; 5: 234-270.
2. Wimo A, Winblad B, Jönsson L. The worldwide societal costs ofdementia: Estimates for 2009. Alzheimers Dementia 2010; 6: 98-103.
3. Yamin G, Ono K, Inayathullah M, Teplow DB. Amyloid β-protein assembly as a therapeutic target of Alzheimer's disease. CurrPharm Des 2008; 14: 3231-3246.
4. Ghosh AK, Gemma S, Tang J. β-Secretase as a therapeutic targetfor Alzheimer's disease. Neurotherapeutics 2008; 5: 399-408.
5. Silvestri R. Boom in the development of non-peptidic -secretase(BACE-1) inhibitors for the treatment of Alzheimer's disease. Med Res Rev 2009; 29: 295-338.
6. Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetyl-cholinesterase from Torpedo californica, a prototypic acetylcho-line-binding protein. Science 1991; 253: 872-879.
7. Lane RM, Potkin SG, Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 2006; 9: 101-124.
8. Lane RM, He Y. Emerging hypotheses regarding the influence ofbutyrylcholinesterase-K variant, APOE e4, and hyperhomocys-teinemia in neurodegenerative dementias. Med Hypothes 2009; 73:230-250.
9. Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcho-linesterase inhibition elevates brain acetylcholine, augments learn-ing and lowers Alzheimer β-amyloid peptide in rodent. Proc NatlAcad Sci USA 2005; 102: 17213-17218.
10. Weinstock M. Selectivity of cholinesterase inhibition: clinicalimplications for the treatment of Alzheimer's disease. CNS Drugs 1999; 12: 307-323.
11. Giacobini E. Cholinesterase inhibitors: new roles and the rapeuticalternatives. Pharmacol Res 2004; 50: 433-440.
12. Venneri A, McGeown WJ, Shanks MF. Empirical evidence ofneuroprotection by dual cholinesterase inhibition in Alzheimer'sdisease. Neuropharmacol Neurotoxicol 2005; 16: 107-110.
13. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition ofacetyl- and butyryl-cholinesterase in the cerebrospinal fluid of pa-tients with Alzheimer's disease by rivastigmine: Correlation withcognitive benefit. J Neural Transm 2002; 109: 1053-1065.
14. Inestrosa NC, Alvarez A, Pérez CA, et al. Acetylcholinesteraseaccelerates assembly of amyloid-β-peptides into Alzheimer's fi-brils: possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-891.
15. Inestrosa NC, Dinamarca MC, Alvarez A. Amyloid cholinesteraseinteractions. Implications for Alzheimer's disease. FEBS J 2008;275: 625-632.
16. Rees T, Hammond PI, Soreq H, Younkin S, Brimijoin S. Acetyl-cholinesterase promotes beta-amyloid plaques in cerebral cortex.Neurobiol Aging 2003; 24: 777-787.
17. Alvarez A, Alarcón R, Opazo C, et al. Stable complexes involvingacetylcholinesterase and amyloid- peptide change the biochemicalproperties of the enzyme and increase the neurotoxicity of Alz-heimer's fibrils. J Neurosci 1998; 18: 3213-3223.
18. Reyes AE, Chacón MA, Dinamarca MC, Cerpa W, Morgan C, Inestrosa NC. Acetylcholinesterase-A complexes are more toxicthan A fibrils in rat hippocampus: effect on rat -amyloid aggre-gation, laminin expression, reactive astrocytosis, and neuronal cellloss. Am J Pathol 2004; 164: 163-174.
19. Rees TM, Berson A, Sklan EH, et al. Memory deficits correlatingwith acetylcholinesterase splice shift and amyloid burden in doublytransgenic mice. Curr Alzheimer Res 2005; 2: 291-300.
20. Hamley IW. Peptide fibrillization. Angew Chem Int Ed 2007; 46:8128-8147.
21. +/) mice showed no memory enhance-ment but hyposensitivity to amnesic drugs. Behav Brain Res 2010;206: 263-273.
22. De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Ine-strosa NC. A structural motif of acetylcholinesterase that promotesamyloid beta-peptide fibril formation. Biochemistry 2001; 40:10447-10457.
23. Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro.Proc Natl Acad Sci USA 2006; 103: 8628-8633.
24. Cavalli A, Bolognesi ML, Capsoni S, et al. A small moleculetargeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Ed 2007; 46: 3689-3692.
25. Pang YP, Quiram P, Jelacic T, Hong F, Brimijoin S. Highly potent,selective, low cost bis-tetrahydroaminacrine inhibitors of acetyl-cholinesterase. J Biol Chem 1996; 271: 23646-2349.
26. Li W, Mak M, Jiang H, et al. Novel anti-Alzheimer's dimer bis(7)-cognitin: cellular and molecular mechanisms of neuroprotectionthrough multiple targets. Neurotherapeutics 2009; 6: 187-201.
27. http: //www.noscira.com.
28. Castro A, Martinez A. Peripheral and dual binding site acetylcho-linesterase inhibitors: implications in treatment of Alzheimer's dis-ease. Mini Rev Med Chem 2001; 1: 267-272.
29. Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-directedligands to combat neurodegenerative diseases. J Med Chem 2008;51: 347-372.
30. Muñoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr Med Chem 2008; 15: 2433-2455.
31. García-Palomero E, Muñoz P, Usan P, et al. Potent -amyloidmodulators. Neurodegener Dis 2008; 5: 153-156.
32. Loudwig S, Nicolet Y, Masson P, et al. Photoreversible inhibitionof cholinesterases: catalytic serine-labeled caged butyrylcholineste-rase. ChemBioChem 2003; 4: 762-767.
33. Savini L, Gaeta A, Fattorusso C, et al. Specific targeting of acetyl-cholinesterase and butyrylcholinesterase recognition sites. Rationaldesign of novel, selective, and highly potent cholinesterase inhibi-tors. J Med Chem 2003; 46: 1-4.
34. Campiani G, Fattorusso C, Butini S, et al. Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. J Med Chem 2005; 48: 1919-1929.
35. Masson P, Froment MT, Fort S, et al. Butyrylcholinesterase-catalyzed hydrolysis of N-methylindoxyl acetate: analysis of volume changes upon reaction and hysteretic behavior. Biochim Bio-phys Acta 2002; 1597: 229-243.
36. Lin G, Chen GH, Lu CP, Yeh SC. QSARs for peripheral anionicsite of butyrylcholinesterase with inhibitions by 4-acyloxy-biphenyl-4'-N-butylcarbamates. QSAR Comb Sci 2005; 24: 943-952.
37. Camps P, Formosa X, Muñoz-Torrero D, Petrignet J, Badia A, ClosMV. Synthesis and pharmacological evaluation of huprine tacrineheterodimers: subnanomolar dual binding site acetylcholinesteraseinhibitors. J Med Chem 2005; 48: 1701-1714.
38. Camps P, Formosa X, Galdeano C, et al. Novel Donepezil basedinhibitors of acetyl- and butyryl cholinesterase and acetylcho-linesterase-induced -amyloid aggregation. J Med Chem 2008; 51:3588-3598.
39. Fang L, Kraus B, Lehmann J, Heilmann J, Zhang Y, Decker M.Design and synthesis of tacrine-ferulic acid hybrids as multi-potentanti-Alzheimer drug candidates. Bioorg Med Chem Lett 2008; 18:2905-2909.
40. Fernández-Bachiller MI, Pérez C, Campillo NE, et al. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's dis-ease, with cholinergic, antioxidant, and neuroprotective properties.Chem Med Chem 2009; 4: 828-41.
41. Fang L, Appenroth D, Decker M, et al. Synthesis and biologicalevaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J Med Chem 2008; 51; 713-716.
42. Elsinghorst PW, Cieslik JS, Mohr K, Tränkle C, Gütschow M. Firstgallamine-tacrine hybrid: Design, and characterization at cho-linesterases and the M2 muscarinic receptor. J Med Chem 2007;50: 5685-5695.
43. Muñoz-Ruiz P, Rubio L, García-Palomero E, et al. Design, synthe-sis, and biological evaluation of dual binding site acetylcho-linesterase inhibitors: New disease-modifying agents for Alz-heimer's disease. J Med Chem 2005; 48: 7223-7233.
44. Bolognesi ML, Cavalli A, Valgimigli L, et al. Multi-target-directeddrug design strategy: From a dual binding site acetylcholinesteraseinhibitor to a trifunctional compound against Alzheimer's disease. J Med Chem 2007; 50: 6446-6449.
45. Harrison SM, Harper AJ, Hawkins J, et al. BACE1 (β-secretase)transgenic and knockout mice: identification of neurochemicaldeficits and behavioral changes. Mol Cell Neurosci 2003; 24: 646-655.
46. McConlogue L, Buttini M, Anderson JP, et al. Partial reduction ofBACE1 has dramatic effects on Alzheimer plaque and synaptic pa-thology in APP transgenic mice. J Biol Chem 2007; 282: 26326-26334.
47. Hong L, Koelsch G, Lin X, et al. Structure of the protease domainof memapsin 2 (β-secretase) complexed with inhibitor. Science g 2000; 290: 150-153.
48. Hong L, Turner RT 3rd, Koelsch G, Shin D, Ghosh AK, Tang J.Crystal structure of memapsin 2 (β-secretase) in complex with aninhibitor OM00-3. Biochemistry 2002; 41: 10963-10967.
49. Mancini F, Naldi M, Cavrini V, Andrisano V. Multiwell fluoromet-ric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors. Anal Bioanal Chem 2007; 388:1175-1183.
50. Fu H, Li W, Luo J, et al. Promising anti-Alzheimer's dimer bis(7)-tacrine reduces β-amyloid generation by directly inhibiting BACE-1 activity. Biochem Biophys Res Commun 2008; 366: 631-6.
51. Rosini M, Andrisano V, Bartolini M, Melchiorre C. Organic com-pounds useful for the treatment of Alzheimer's disease, their useand method of preparation. WO 2006/080043 A2.
52. Piazzi L, Cavalli A, Colizzi F, et al. Multi-target-directed coumarinderivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem 2008; 18: 423-426.
53. Camps P, Formosa X, Galdeano C, et al. Pyrano [3,2-c]quinoline 6-chlorotacrine hybrids as a novel family of acetylcho-linesterase- and -amyloid-directed anti-Alzheimer compounds. J Med Chem 2009; 52: 5365-5379.
54. Raves ML, Harel M, Pang YP, Silman I, Kozikowski AP Sussman JL. Structure of acetylcholinesterase complexed with the nootropicalkaloid, (-)-huperzine A. Nature Struct Biol 1997; 4: 57-63.
55. Dvir H, Jiang HL, Wong DM, et al. X-ray structures of Torpedocalifornica acetylcholinesterase complexed with (+)-huperzine Aand (-)-huperzine-B: Structural evidence for an active site rear-rangement. Biochemistry 2002; 41: 10810-10818.
56. Barril X, Kalko SG, Orozco M, Luque FJ. Rational design ofreversible acetylcholinesterase inhibitors. Mini Rev Med Chem 2002; 2: 27-36.
57. Harel M, Schalk I, Ehret-Sabatier L, et al. Quaternary ligandbinding to aromatic residues in the active-site gorge of acetylcho-linesterase. Proc Nat Acad Sci USA 1993; 90: 9031-9035.
58. Camps P, Muñoz-Torrero D. Tacrine-huperzine A hybrids (hupri-nes): A new class of highly potent and selective acetylcho-linesterase inhibitors of interest for the treatment of Alzheimer dis-ease. Mini Rev Med Chem 2001; 1: 163-174.
59. Camps P, El Achab R, Görbig DM, et al. Synthesis, in vitro phar-macology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potentialinterest for the treatment of Alzheimer's disease. J Med Chem 1999; 42: 3227-42.
60. Barril X, Orozco M, Luque FJ. Predicting relative binding freeenergies of tacrine-huperzine A hybrids as inhibitors of acetylcho-linesterase. J Med Chem 1999; 42: 5110-5119.
61. Camps P, El Achab R, Morral J, et al. New tacrine-huperzine Ahybrids (huprines): Highly potent tight-binding acetylcho-linesterase inhibitors of interest for the treatment of Alzheimer'sdisease. J Med Chem 2000; 43: 4657-4666.
62. Dvir H, Wong DM, Harel M, et al. 3D structure of Torpedo cali-fornica acetylcholinesterase complexed with huprine X at 2.1 Åresolution: kinetic and molecular dynamic correlates. Biochemistry 2002; 41: 2970-2981.
63. Camps P, Gómez E, Muñoz-Torrero D, et al. Binding of 13-amidopurines to acetylcholinesterase: Exploring the ligand-inducedconformational change of the Gly117-Gly118 peptide bond in theoxyanion hole. J Med Chem 2006; 49: 6833-6840.
64. Pilger C, Bartolucci C, Lamba D, Tropsha A, Fels G. Accurateprediction of the bound conformation of galanthamine in the activesite of Torpedo californica acetylcholinesterase using moleculardocking. J Mol Graphics Model 2001; 19: 288-296.
65. Bartolucci C, Pilger C, Fels G, Lamba D. Three-dimensionalstructure of a complex of galanthamine (Nivalin) with acetylcho-linesterase from Torpedo californica: Implications for the design ofnew anti-Alzheimer drugs. Proteins: Struct Funct Bioinf 2001; 42:182-191.
66. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL. Struc-ture of acetylcholinesterase complexed with (-)-galanthamine at2.3 Å resolution. FEBS Lett 1999; 463: 321-326.
67. Bourne Y, Taylor P, Radi Z, Marchot P. Structural insights intoligand interactions at the acetylcholinesterase peripheral anionicsite. EMBO J 2003; 22: 1-12.
68. Cavalli A, Bottegoni G, Raco C, De Vivo M, Recanatini MA.Computational study of the binding of propidium to the peripheralanionic site of human acetylcholinesterase. J Med Chem 2004; 47:3991-3999.
69. Szegletes T, Mallender WD, Rosenberry TL. Nonequilibriumanalysis alters the mechanistic interpretation of inhibition of acetyl-cholinesterase by peripheral site ligands. Biochemistry 1998; 37:4206-4216.
70. Harel M, Sonoda LK, Silman I, Sussman JL, Rosenberry TL.Crystal structure of thioflavin T bound to the peripheral site ofTorpedo californica acetylcholinesterase reveals how thioflavin Tacts as a sensitive fluorescent reporter of ligand binding to the acy-lation site. J Am Chem Soc 2008; 130: 7856-7861.
71. Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterasecomplexed with E2020 (Aricept): implications for the design ofnew anti-Alzheimer drugs. Structure 1999; 7: 297-307.
72. Rydberg EH, Brumshtein B, Greenblatt HM, et al. Complexes ofalkylene-linked tacrine dimers with Torpedo californica acetylcho-linesterase: Binding of bis(5)-tacrine produces a dramatic rear-rangement in the active-site gorge. J Med Chem 2006; 49: 5491-5500.
73. Colletier JP, Sanson B, Bachon F, et al. Conformational flexibilityin the peripheral site of Torpedo californica acetylcholinesteraserevealed by the complex structure with a bifunctional inhibitor. J Am Chem Soc 2006; 128: 4526-4527.
74. Gemma S, Gabellieri E, Huleatt P, et al. Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites. J Med Chem 2006; 49: 3421-3425.
75. Haviv H, Wong DM, Greenblatt HM, et al. Crystal packing mediates enantioselective ligand recognition at the peripheral site ofacetylcholinesterase. J Am Chem Soc 2005; 127: 11029-11036.
76. Bourne Y, Kolb HC, Radic Z, Sharpless KB, Taylor P, Marchot P.Freeze-frame inhibitor captures acetylcholinesterase in a uniqueconformation. Proc Natl Acad Sci USA 2004; 101: 1449-1454.
77. Senapati S, Bui JM, McCammon JA. Induced fit in mouse acetyl-cholinesterase upon binding a femtomolar inhibitor: a moleculardynamics study. J Med Chem 2005; 48: 8155-8162.
78. Wong DM, Greenblatt HM, Dvir H, et al. Acetylcholinesterasecomplexed with bivalent ligands related to huperzine A: experi-mental evidence for species-dependent protein-ligand complemen-tarity. J Am Chem Soc 2003; 125: 363-373.
79. Greenblatt HM, Guillou C, Guénard D, et al. The complex of abivalent derivative of galanthamine with Torpedo acethylcho-linesterase displays drastic deformation of the active-site gorge:Implications for structure-based drug design. J Am Chem Soc 2004; 126: 15405-11.
80. Bartolucci C, Haller LA, Jordis U, Fels G, Lamba D. ProbingTorpedo californica acetylcholinesterase catalytic gorge with twonovel bis-functional galanthamine derivatives. J Med Chem 2010;53: 745-751.
81. Adcock SA, McCammon JA. Molecular dynamics: survey ofmethods for simulating the activity of proteins. Chem Rev 2006;106: 1589: 615.
82. Kua J, Zhang Y, McCammon JA. Studying enzyme binding speci-ficity in acetylcholinesterase using a combined molecular dynamicsand multiple docking approach. J Am Chem Soc 2002; 124: 8260-8267.
83. Bartolucci C, Perola E, Cellai L, Brufani M, Lamba D. "Backdoor" opening implied by the crystal structure of a carbamoylatedacetylcholinesterase. Biochemistry 1999; 38: 5714-5719.
84. Rampa A, Bisi A, Valenti P, et al. Acetylcholinesterase inhibitors:Synthesis and structure-activity relationships of [N-methyl-N-(3-alkylcarbamoyloxyphenyl)-methyl]aminoalkoxyheteroaryl derivatives. J Med Chem 1998; 41: 3976-3986.
85. Rampa A, Piazzi L, Belluti F, et al. Acetylcholinesterase inhibitors:SAR and kinetic studies on [N-methyl-N-(3-alkylcarbamoyloxyphenyl)-methyl]aminoalkoxyaryl derivatives. J Med Chem 2001; 44: 3810-3820.
86. Belluti F, Rampa A, Piazzi L, et al. Cholinesterase inhibitors:Xanthostigmine derivatives blocking the acetylcholinesterase-induced -amyloid aggregation. J Med Chem 2005; 48: 4444-4456.
87. Nachon F, Nicolet Y, Viguié N, et al. Engineering of a monomericand low-glycosylated form of human butyrylcholinesterase. Eur J Biochem 2002; 269: 630-637.
88. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F. Crystal structure of human butyrylcholinesterase and of its com-plexes with substrate and products. J Biol Chem 2003; 278: 41141-41147.
89. Ngamelue MN, Homma K, Lockridge O, Asojo OA. Crystallization and X-ray structure of full-length recombinant human butyryl-cholinesterase. Acta Cryst 2007; F63: 723-727.
90. Radic Z, Pickering NA, Vellom DC, Camp S, Taylor P. Threedistinct domains in the cholinesterase molecule confer selectivityfor acetyl- and butyrylcholinesterase inhibitors. Biochemistry 1993;32: 12074-12084.
91. Butini S, Campiani G, Borriello M, et al. Exploiting protein fluc-tuations at the active-site gorge of human cholinesterases: Futureoptimization of the design strategy to develop extremely potent in-hibitors. J Med Chem 2008, 51: 3154-3170.
92. Elsinghorst PW, Cieslik JS, Mohr K, Tränkle C, Gütschow M. Firstgallamine-tacrine hybrid: Design and characterization at cho-linesterases and the M2 muscarinic receptor. J Med Chem 2007; 50:5685-95.
93. Tumiatti V, Milelli A, Minarini A, et al. Structure-activity relation-ships of acetylcholinesterase noncovalent inhibitors based on apolyamine backbone. 4. Further investigation on the inner spacer. J Med Chem 2008; 51: 7308-7312.
94. Pan L, Tan JH, Hou JQ, Huang SL, Gu LQ, Huang ZS. Design,synthesis and evaluation of isainditigotone derivates as acetylcho-linesterase and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett 2008; 18: 3790-3793.
95. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavageof Alzheimer's amyloid precursor protein by the transmembraneaspartic protease BACE. Science 1999; 286: 735-741.
96. Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchoredaspartyl protease with Alzheimer's disease beta-secretase activity.Nature 1999; 402: 533-537.
97. Sinha S, Anderson JP, Barbour R, et al. Purification and cloning ofamyloid precursor protein beta-secretase from human brain. Nature 1999; 402: 537-540.
98. Sinha S, Lieberburg I. Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA 1999; 9: 11049-11053.
99. Ghosh AK, Bilcer G, Harwood C, et al. Structure-based design:potent inhibitors of human brain memapsin 2 (beta-secretase). J Med Chem 2001; 44: 2865-2868.
100. John V, Beck JP, Bienkowski MJ, Sinha S, Heinrikson RL. Humanbeta-secretase (BACE) and BACE inhibitors. J Med Chem 2003;46: 4625-4630.
101. Hong L, Koelsch G, Lin X, et al. Structure of the protease domainof memapsin 2(beta-secretase) complexed with inhibitor. Science 2000; 290: 150-153.
102. Ghosh AK, Shin D, Downs D, et al. Design of potent inhibitors forhuman brain memapsin 2 (β-secretase). J Am Chem Soc 2000; 122:3522-3523.
103. Hong L, Tang J. Flap position of free memapsin 2 (beta-secretase),a model for flap opening in aspartic protease catalysis. Biochemistry 2004; 43: 4689-4695.
104. Patel S, Vuillard L, Cleasby A, Murray CW, Yon J. Apo andinhibitor complex structures of BACE (beta-secretase). J Mol Biol 2004; 343: 407-416.
105. Shimizu H, Tosaki A, Kaneko K, Hisano T, Sakurai T, Nukina N.Crystal structure of an active form of BACE1, an enzyme resposible for amyloid beta protein production. Mol Cell Biol 2008; 28:3663-3971.
106. Yu N, Hayik SA, Wang B, Liao N, Reynolds CH, Merz KM Jr.Assigning the protonation states of the key aspartates in β-secretaseusing QM/MM X-ray structure refinement. J Chem Theory Comput 2006; 2: 1057-69.
107. Polgár T, Keserü GM. Virtual screening for β-secretase (BACE1)inhibitors reveals the importance of protonation states at Asp32 andAsp228. J Med Chem 2005; 48: 3749-3755.
108. Park H, Lee S. Determination of the active site protonation state of-secretase from molecular dynamics simulation and docking experiment: Implications for structure-based inhibitor design. J AmChem Soc 2003; 125: 16416-16422.
109. Rajamani R, Reynolds CH. Modeling the protonation states of thecatalytic aspartates in β-secretase. J Med Chem 2004; 47: 5159-5166.
110. Huang D, Caflisch A. Efficient evaluation of binding free energyusing continuum electrostatics solvation. J Med Chem 2004; 47:5791-5797.
111. Murray CW, Callaghan O, Chessari G, et al. Application of frag-ment screening by X-ray crystallography to beta-secretase. J Med Chem 2007; 50: 1116-1123.
112. Hanessian S, Yun H, Hou Y, et al. Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic andheterocyclic peptidomimetics. J Med Chem 2005; 48: 5175-5190.
113. Stachel SJ, Coburn CA, Steele TG, et al. Conformationally biasedP3 amide replacvement of beta-secretase inhibitors. Bioorg Med Chem Lett 2006; 16: 641-644.
114. Freslkos JN, Fobian YM, Benson TE, et al. Design of potentinhibitors of human beta-secretase. Part 2. Bioorg Med Chem Lett 2007; 17: 78-81.
115. Turner RT III, Hong L, Koelsch G, Ghosh AK, Tang J. Structurallocations and functional roles of new subsites S5, S6, and S7 inmemapsin 2 (beta-secretase) Biochemistry 2005; 44: 105-112.
116. Hanessian S, Yang G, Rondeau JM, Neumann U, Betschart C,Tintelnot-Blomley M. Structure-based design and synthesis of mac-roheterocyclic peptidomimetic inhibitors of the aspartic proteasebeta-site amyloid precursor protein cleaving enzyme (BACE). J Med Chem 2006; 49: 4544-4567.
117. Coburn CA, Stachel SJ, Li YM, et al. Identification of a smallmolecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. J Med Chem 2004; 47: 6117-6119.
118. Stachel SJ, Coburn CA, Steele TG, et al. Structure-based design ofpotent and selective cell-permeable inhibitors of human beta-secretase (BACE-1). J Med Chem. 2004; 47: 6447-6450.
119. Congreve M, Aharony D, Albert J, et al. Application of fragmentscreening by X-ray crystallography to the discovery of aminopyri-dines as inhibitors of beta-secretase. J Med Chem 2007; 50: 1124-32.
120. Edwards PD, Albert JS, Sylvester M, et al. Application of fragment-based lead generation to the discovery of novel, cyclicamidine beta-secretase inhibitors with nanomolar potency, cellularactivity, and high ligand efficiency. J Med Chem 2007; 50: 5912-25.
121. Cole DC, Manas ES, Stock JR, et al. Acylguanidines as small-moleculae b-secretase inhibitors. J Med Chem 2006; 49: 6158-61.
122. Cole DC, Stock JR, Chopra R, et al. Acylguanidine inhibitors ofbeta-secretase: optimization of the pyrrole ring substituents extend-ing into the S1 and S3 substrate binding pockets. Bioorg MedChem Lett 2008; 18: 1063-6.
123. Malamas MS, Erdei J, Gunawan I, et al. Aminoimidazoles aspotent and selective human beta-secretase (BACE1) inhibitors. J Med Chem 2009; 52: 6314-23.
124. Malamas MS, Barnes K, Johnson M, et al. Di-substituted pyridinylaminohydantoins as potent and highly selective human beta-secretase (BACE1) inhibitors. Bioorg Med Chem 2010; 18: 630-9.
125. Nowak P, Cole DC, Aulabaugh A, et al. Discovery and initialoptimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors. Bioorg Med Chem Lett 2010; 20:632-5.
126. Godemann R, Madden J, Krämer J, et al. Fragment-based discov-ery of BACE1 inhibitors using functional analysis. Biochemistry 2009; 48: 10743-51.
127. Wang YS, Strickland C, Voigt JH, et al. Application of fragment-based NMR screening, X-ray crystallography, structure-based de-sign, and focused chemical library design to identify novel μMleads for the development of nM BACE-1 (-site APP cleaving en-zyme 1) inhibitors. J Med Chem 2010; 53: 942-50.
128. Zhu Z, Sun ZY, Ye Y, et al. Discovery of cyclic acylguanidines ashighly potent and selective -site amyloid cleaving enzyme(BACE) inhibitors: Part I - Inhibitor design and validation. J MedChem 2010; 53: 951-65.